公开(公告)号：US20170369549A1

公开(公告)日：2017-12-28

申请号：US15668824

申请日：2017-08-04

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Robert James PEACH ,  Joseph Naemura ,  Peter S. Linsley ,  Jurgen Bajorath

IPC: C07K14/725 ,  A61K38/17 ,  C07K14/705 ,  C12N5/0783 ,  C07H21/04 ,  A61K39/395 ,  A61K38/00 ,  A61K39/00

CPC classification number: C07K14/7051 ,  A61K38/00 ,  A61K38/1774 ,  A61K39/39 ,  A61K39/3955 ,  A61K2039/505 ,  C07H21/04 ,  C07K14/70521 ,  C07K2319/30 ,  C12N5/0636 ,  C12N2501/51

Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

公开(公告)号：US20180134764A9

公开(公告)日：2018-05-17

申请号：US15668824

申请日：2017-08-04

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Robert James PEACH ,  Joseph Naemura ,  Peter S. Linsley ,  Jurgen Bajorath

IPC: C07K14/725 ,  C07H21/04 ,  A61K38/17 ,  A61K39/395 ,  C07K14/705 ,  C12N5/0783 ,  A61K39/00 ,  A61K38/00

CPC classification number: C07K14/7051 ,  A61K38/00 ,  A61K38/1774 ,  A61K39/39 ,  A61K39/3955 ,  A61K2039/505 ,  C07H21/04 ,  C07K14/70521 ,  C07K2319/30 ,  C12N5/0636 ,  C12N2501/51

Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

公开(公告)号：US20150071914A1

公开(公告)日：2015-03-12

申请号：US14289715

申请日：2014-05-29

Applicant: Bristol-Myers Squibb Company

Inventor： Robert James PEACH ,  Joseph Naemura ,  Peter S. Linsley ,  Jurgen Bajorath

IPC: C07K14/725 ,  A61K39/395 ,  A61K38/17

CPC classification number: C07K14/7051 ,  A61K38/00 ,  A61K38/1774 ,  A61K39/39 ,  A61K39/3955 ,  A61K2039/505 ,  C07H21/04 ,  C07K14/70521 ,  C07K2319/30 ,  C12N5/0636 ,  C12N2501/51

Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

Abstract translation: 本发明提供与野生型CTLA4或非突变型CTLA4Ig相比，其结合比CD80和/或CD86抗原更高亲合力的可溶性CTLA4突变体分子。 可溶性CTLA4分子具有包含CTLA4细胞外结构域的第一个氨基酸序列，其中S25-R33区域和M97-G107区域内的某些氨基酸残基被突变。 本发明的突变分子还可以包括增加突变分子的溶解度的第二个氨基酸序列。